Madopar (Benserazide, Levodopa)

Madopar acts on the dopaminergic pathway to alleviate motor symptoms of Parkinsonian disorders.

• Parkinson's disease: improves tremor, rigidity, bradykinesia and overall motor function.
• Parkinsonian syndrome: provides symptomatic relief of movement impairments.
• Secondary Parkinsonism: offers motor symptom control when caused by drug‑induced or vascular factors.

• Levodopa crosses the blood‑brain barrier and is decarboxylated to dopamine within central neurons, replenishing depleted dopaminergic transmission. Benserazide, a peripheral aromatic L‑amino‑acid decarboxylase inhibitor, blocks conversion of levodopa outside the brain, increasing the amount that reaches the CNS and reducing peripheral side effects such as nausea. This synergistic action results in more stable plasma levels and enhances clinical efficacy while minimizing gastrointestinal adverse events.

Adverse reactions to Madopar may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset, often early in therapy.
• Orthostatic hypotension: dizziness upon standing due to vasodilation.
• Headache: transient cranial discomfort.
• Insomnia: difficulty initiating or maintaining sleep.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Dyskinesia: involuntary, erratic movements that may be disabling.
• Hallucinations or psychosis: visual or auditory disturbances, especially in older patients.
• Severe hypotension: marked blood pressure drop leading to fainting.
• Neuroleptic malignant syndrome: rare life‑threatening reaction when combined with dopamine antagonists.

Careful assessment and monitoring are required when prescribing Madopar.

• Dose titration: start with a low dose and increase gradually to balance efficacy and tolerability.
• Blood pressure monitoring: watch for orthostatic hypotension, especially in the elderly.
• Psychiatric evaluation: assess for hallucinations, confusion or mood changes during treatment.
• Contraindication in narrow‑angle glaucoma: avoid use as it may increase intra‑ocular pressure.
• Pregnancy and lactation: category C; use only if potential benefit justifies potential risk.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Madopar can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors: may cause hypertensive crisis when combined with levodopa.
• Antipsychotics (e.g., haloperidol): block dopamine receptors and reduce therapeutic benefit.
• Pyridoxine (vitamin B6): enhances peripheral levodopa metabolism, decreasing central availability.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: additive effect on blood pressure, increasing risk of hypotension.
• SSRIs or SNRIs: potential for serotonin syndrome when used with MAO‑I precursors.
• Iron or calcium supplements: may chelate levodopa in the gut, reducing absorption.